Haleon (LON:HLN) Price Target Cut to GBX 400 by Analysts at Jefferies Financial Group

Key Points

• Jefferies cut its price target on Haleon to GBX 400 (from GBX 450) but maintained a "buy" rating, implying roughly a 19.13% upside from the prior close.
• Analyst consensus is a "Moderate Buy" with an average target of GBX 398.67, based on four Buys, one Hold and one Sell, and individual targets ranging from GBX 335 to GBX 512.
• HLN opened around GBX 335.76, trades near its 50/200-day averages (~GBX 371), has a market cap of £29.94bn and a P/E of 18.15, and insider Brian McNamara sold 704,974 shares in March.

Haleon (LON:HLN - Get Free Report) had its price objective reduced by equities researchers at Jefferies Financial Group from GBX 450 to GBX 400 in a research note issued to investors on Tuesday,Digital Look reports. The firm presently has a "buy" rating on the stock. Jefferies Financial Group's price objective suggests a potential upside of 19.13% from the stock's previous close.

Several other research firms have also issued reports on HLN. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Haleon from GBX 340 to GBX 335 and set a "buy" rating for the company in a report on Thursday, January 22nd. Berenberg Bank reissued a "buy" rating and set a GBX 512 price target on shares of Haleon in a research report on Thursday, April 30th. Finally, Royal Bank Of Canada reissued a "sector perform" rating and set a GBX 370 price target on shares of Haleon in a research report on Thursday, April 30th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of GBX 398.67.

Haleon Price Performance

HLN stock opened at GBX 335.76 on Tuesday. The firm has a 50 day moving average price of GBX 371.46 and a 200-day moving average price of GBX 371.01. Haleon has a 52-week low of GBX 325.10 and a 52-week high of GBX 419.50. The firm has a market capitalization of £29.94 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 1.49 and a beta of 0.33. The company has a debt-to-equity ratio of 52.26, a quick ratio of 0.93 and a current ratio of 0.92.

Haleon (LON:HLN - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a net margin of 12.59% and a return on equity of 6.43%. Equities research analysts forecast that Haleon will post 19.5033282 EPS for the current fiscal year.

Insider Buying and Selling at Haleon

In other news, insider Brian McNamara sold 704,974 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of GBX 368, for a total value of £2,594,304.32. 0.01% of the stock is owned by company insiders.

About Haleon

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.